Research Peptide News

FDA Proposes Blocking Large-Scale Compounding of Semaglutide and Tirzepatide — What It Means

The FDA proposed on April 30, 2026 to exclude semaglutide and tirzepatide from the 503B bulks list — the regulatory pathway that allows outsourcing facilities to compound these drugs at scale for telehealth providers. The agency stated it found no clinical need for bulk compounding of either compound, a move that directly supports Novo Nordisk and Eli Lilly's efforts against unauthorized versions. The proposal also includes liraglutide. A public comment period runs until June 29 before a final decision is issued. While 503A pharmacies that compound for individual patients may be less affected operationally, the proposal signals continued tightening of the compounding landscape for GLP-1 compounds following the shortage list removals in 2024 and 2025.

FDA Officially Confirms 12 Peptides Removed from Category 2 — Full List and What It Means

On April 15, 2026, the FDA formally announced it will imminently remove 12 bulk drug substances from Category 2 — the restricted list that had prevented compounding pharmacies from legally producing them. The confirmed compounds are: BPC-157, LL-37, DiHexa, DSIP, Epithalon, GHK-Cu (injectable), KPV, PEG-MGF, Melanotan II, MOTS-C, Semax, and TB-500. Non-injectable GHK-Cu is flagged for further review before February 2027. The FDA's July 23–24 advisory panel is now expected to explore moving these compounds to full Category 1 approval. This is the most significant regulatory development for research compound access in years — and the first time the official confirmed list of all 12 compounds has been publicly documented by a federal agency.

FDA Schedules July Advisory Panel to Decide Whether Restricted Peptides Return to Legal Compounding

The FDA announced it will convene an outside advisory committee on July 23–24, 2026 to review whether compounding pharmacies should be allowed to manufacture certain peptides removed from the allowable list in 2023. The panel will weigh evidence on seven compounds — including BPC-157 and TB-500 — while five additional peptides are slated for a separate meeting before February 2027. The move follows HHS Secretary RFK Jr.'s public push to restore access and represents the first formal FDA step toward potential reclassification, though approval is far from guaranteed given the agency's acknowledged gaps in human safety data.

Stanford Discovers 'Natural Ozempic' Peptide That Suppresses Appetite Without Nausea or Muscle Loss

Scientists at Stanford Medicine identified a naturally occurring peptide called BRP (BRINP2-Related-Peptide) using artificial intelligence to screen thousands of prohormone fragments. In animal testing, a single injection reduced food intake by up to 50% within an hour, and 14 days of daily injections produced significant fat loss with no muscle wasting, no nausea, and no changes in anxiety or digestion. Critically, BRP works through entirely different brain and metabolic pathways than GLP-1 or semaglutide — meaning it could complement existing GLP-1 research or serve as an alternative for subjects that don't respond well to GLP-1 agonism. The study was published in Nature and the senior author has co-founded a company planning human clinical trials. This is the first major AI-discovered appetite peptide to reach this level of validation.

CBP Seizes 5,000 Smuggled Research Compound Shipments in Major Cincinnati Bust

U.S. Customs and Border Protection officers at the Port of Cincinnati seized approximately 5,000 individual smuggled shipments of research compounds from December 2025 through March 2026. Compounds included retatrutide, semaglutide, tirzepatide, MOTS-C, Semax, and cagrilintide — all mis-manifested and shipped from China. A separate Utah physician was also indicted for selling non-FDA-approved compounds to over 200 patients. A Texas testing lab reports one third of compounds it tests fail basic quality checks.

GLP-1 Pills Are Here: FDA Approves Two Oral Weight Loss Medications in 4 Months

The FDA approved Novo Nordisk's Wegovy pill in December 2025 and Eli Lilly's Foundayo on April 1, 2026 — the fastest drug approval since 2002. Two oral GLP-1 options now exist for the first time, with both starting at $149/month out of pocket. Here's how they compare and what it means for researchers.

New 2026 Research Reveals How MOTS-c Improves Muscle Energy at the Cellular Level

Researchers at the University of Copenhagen published new findings showing MOTS-c enhances skeletal muscle mitochondrial energy production through PGC-1α and AMPK pathways — without simply adding more mitochondria. The study also found MOTS-c significantly reduces oxidative stress markers in muscle tissue.

Third-Party Testing Audit: 1 in 4 Peptide Suppliers Still Lack Verifiable COAs in 2026

A Best Pep Prices review of 60+ domestic US peptide suppliers in Q1 2026 found that approximately 25% lack publicly verifiable third-party Certificates of Analysis — either providing no COA, providing supplier-generated documentation only, or linking to COAs from testing labs that cannot be independently verified. The finding matters because peptide purity directly affects research reproducibility and dosing accuracy. A 10mg vial of 85% pure BPC-157 delivers meaningfully less active compound than one tested at 98%+. Suppliers with verified third-party COAs are identified in our supplier comparison tool.

RFK Jr. Announces 14 Research Compounds Returning to Legal Compounding — What It Means

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 research compounds previously restricted under the FDA's Category 2 list will return to Category 1 status — restoring legal access through licensed compounding pharmacies with a physician's prescription. Compounds expected to return include BPC-157, TB-500, Thymosin Alpha-1, CJC-1295, Ipamorelin, AOD-9604, Selank, and Semax. The formal FDA publication has not yet been released as of April 2026. Melanotan II, GHRP-2, GHRP-6, LL-37, and PEG-MGF are expected to remain restricted.

Major Orthopaedic Journal Reviews BPC-157, TB-500, GHK-Cu and More in Landmark 2026 Paper

A comprehensive review published in the Journal of the American Academy of Orthopaedic Surgeons covers BPC-157, TB-500, GHK-Cu, Ipamorelin, CJC-1295, Tesamorelin, Sermorelin, AOD-9604, Epithalon, Selank, and Semax — examining their mechanisms, tissue regeneration potential, and where human evidence currently stands. The paper notes these compounds are generating significant patient demand and that orthopaedic providers need to understand the current landscape.

Tirzepatide Shows 22% Body Weight Reduction in Extended Phase 3 Trial

A multi-year extension study confirmed tirzepatide maintains significant weight loss beyond 72 weeks, with subjects averaging 22.4% total body weight reduction at the highest dose cohort. Lean mass preservation remained a notable advantage over GLP-1 monotherapies.

FDA Issues Draft Guidance on Compounded Peptide Oversight

The FDA released updated draft guidance clarifying its position on compounded peptide availability under Section 503A and 503B. The guidance signals increased regulatory attention on the broader peptide supply chain without directly affecting research-use suppliers.

GLP-1 Regulatory Landscape 2025: Shortage Removal, Compounding Restrictions, and What It Means for Researchers

The FDA removed semaglutide from the drug shortage list in October 2024 and tirzepatide in early 2025, eliminating the legal basis for bulk compounding under 503A/503B frameworks. Compounding pharmacy trade groups filed legal challenges, and court proceedings across multiple jurisdictions were ongoing as of early 2025. Research-grade GLP-1 compounds occupy a legally distinct category — not pharmaceutical, not compounded — but FDA enforcement attention on the space is increasing. What was permissible under shortage conditions in 2023 is not necessarily permissible in 2025.

AI Is Now Designing Peptides From Scratch — A Shift That Could Reshape Research Compound Development

A major review published in ACS Biochemistry in April 2026 documents how artificial intelligence has fundamentally changed peptide discovery. Where traditional workflows required slow, iterative lab screening to find peptides that bind specific targets, AI-driven design now enables researchers to generate isoform-specific binders, multi-objective assay compounds, and motif-specific tools on demand. The review covers both sequence-based and structure-based AI design paradigms and outlines how each supports distinct classes of research peptides. The practical implication: the pipeline of novel research compounds is about to accelerate dramatically. Compounds that would have taken years to discover and characterize can now be designed and validated in months. This is the infrastructure story behind why 140+ peptides are currently in clinical trials and why that number will likely double by 2030.

University Researchers Warn: Anti-Aging Peptide Trend Outpacing the Evidence

Three researchers from the University of Queensland and UNSW Sydney published a detailed safety assessment of the injectable peptide trend in April 2026, finding that claims for GHK-Cu, BPC-157, and TB-500 rely almost entirely on animal and cell studies — not humans. The authors identified three primary risk categories: product quality failures in unregulated supply chains, biological risks including theoretical tumor promotion and endocrine disruption, and injection hazards. They note that only three small, poorly controlled human studies exist for BPC-157 as of early 2026, and that 'there are no high-quality trials reflecting real-world use.'

Annals of Internal Medicine Publishes Case Report: Retatrutide Causes Severe Intractable Diarrhea

A peer-reviewed case report published April 7, 2026 in Annals of Internal Medicine: Clinical Cases documents a dramatic adverse event from retatrutide — a novel triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The case highlights unintended gastrointestinal consequences beyond the nausea and vomiting already catalogued with GLP-1 and dual GIP/GLP-1 agonists, and the authors explicitly call for increased regulatory measures around the marketing of these treatments. The report is notable because it comes from a peer-reviewed journal co-published by the American College of Physicians and the American Heart Association — giving it significant institutional weight. As retatrutide gains popularity in research settings ahead of its expected Phase 3 data and potential FDA submission, this case adds important safety context that researchers should be aware of.

Science.org Chemist Weighs In: What the Peptide Craze Looks Like From Inside the Lab

Derek Lowe, medicinal chemist and longtime drug industry commentator at Science.org (AAAS), published a frank assessment of the mail-order peptide phenomenon on April 6, 2026. Writing from a chemist's perspective, Lowe distinguishes between peptides as scientists understand them and 'Peptides!' as marketed wellness products — noting the enormous chemical complexity of the space, why oral administration doesn't work for most compounds, and what it means that regulatory scrutiny of human data requirements is weakening.

ER Doctor Writes in STAT News: Patients Are Choosing BPC-157 Over Statins — and It Reveals a Deeper Problem

A board-certified emergency physician and former U.S. Navy flight surgeon published a candid essay in STAT News in April 2026 describing a patient who stopped a prescribed statin — despite a coronary artery calcium score of 280 and a family history of fatal heart disease — while continuing to self-inject BPC-157 three times a week for a knee injury. The physician's diagnosis: in consumer health culture, the volume of evidence behind a therapy has become inversely correlated with public trust in it. The essay is notable because the author explicitly states he is not opposed to peptide therapy — he runs a longevity and metabolic optimization practice — but argues the current dynamic is wholesale substitution of consumer enthusiasm for clinical evidence. A rare, nuanced perspective from inside mainstream medicine on why research compounds are winning the trust war.

Peptide Market Sees Price Compression as US Supplier Count Crosses 60 in 2026

The domestic research peptide market has grown from roughly 20 trackable suppliers in 2022 to over 60 in early 2026, according to Best Pep Prices data. The increase in competition has produced meaningful price compression on core compounds: BPC-157 prices have fallen approximately 25–35% since 2023, and TB-500 is similarly down. GLP-1 compounds remain the exception — semaglutide and tirzepatide pricing has held relatively firm due to raw material costs and consistent demand. New entrants are increasingly differentiating on COA transparency and third-party testing rather than price alone, which researchers should view as a positive development for sourcing quality.

FDA Approves Icotrokinra — the First Oral Targeted Peptide to Block the IL-23 Receptor

On March 18, 2026, the FDA approved Johnson & Johnson's Icotyde (icotrokinra) for moderate-to-severe plaque psoriasis — marking the first FDA approval of an oral targeted peptide that works by blocking a specific receptor (IL-23R). In the pivotal ICONIC-ADVANCE trials, approximately 70% of patients achieved clear or near-clear skin at week 16, outperforming the oral comparator deucravacitinib. Adverse-reaction rates were within 1.1% of placebo through week 16 with no new safety signals through week 52. The approval is a landmark for peptide drug delivery science, showing that a peptide can achieve high-affinity receptor binding orally — a longstanding challenge for the drug class.

Longevity Researchers Are Converging on Four Peptides: Epithalon, MOTS-C, SS-31, and GHK-Cu

Analysis of 2025–2026 longevity research literature shows a convergence around four research peptides among scientists studying aging mechanisms: Epithalon (telomerase activation via Khavinson's work and replications), MOTS-C (mitochondrial AMPK activation and insulin sensitivity in aging models), SS-31/Elamipretide (cardiolipin binding and mitochondrial membrane protection with multiple independent replications), and GHK-Cu (gene expression changes affecting 4,000+ genes in aging tissue). Each addresses a distinct hallmark of aging — telomere biology, mitochondrial function, and tissue repair — which may explain why they appear together in compound aging research protocols. None has large-scale human trial data; all have preclinical and small human study data.

FDA Issues 30 Warning Letters to Telehealth Companies Over Illegal Compounded GLP-1 Marketing

On February 20, 2026, the FDA issued 30 warning letters to telehealth companies making false or misleading advertising claims about compounded semaglutide and tirzepatide. Primary violations included implying compounded products are equivalent to FDA-approved drugs and obscuring the fact that compounded versions are not FDA-reviewed for safety or efficacy. Companies were given 15 days to respond or face product seizure and injunctions. With semaglutide and tirzepatide no longer on the FDA shortage list, the legal basis for bulk compounding has expired — and this enforcement round signals the agency is actively moving against the remaining market.

First Prospective BPC-157 Human Study Announced: Croatian Team Targets Tendon Repair

Researchers at the University of Zagreb — the institution behind much of the foundational BPC-157 preclinical work — announced in early 2026 a planned prospective observational study in human subjects with Achilles tendon injuries. The study is observational rather than a randomized controlled trial, meaning it will track outcomes in subjects who self-administer the compound rather than randomizing participants to treatment arms. While this design limits causal inference, it represents the first formal prospective data collection effort in humans and will produce the first structured human safety and outcome data for BPC-157. The study is expected to enroll 40–60 subjects over 18 months.

STAT News Deep Dive: What the Science on BPC-157 Actually Shows — and What It Doesn't

STAT News published a detailed investigation into BPC-157 in February 2026, finding that nearly all research originates from a single Croatian lab led by Predrag Sikiric and has never been independently replicated at scale. In human data, only three small pilot studies exist as of early 2026 — none with a proper control group. The FDA added BPC-157 to its prohibited compounding list in 2023 citing incomplete safety data and potential immune responses. Despite this, the compound is increasingly promoted by wellness influencers and clinics. The article notes the RFK administration has signaled openness to revisiting restrictions, setting up a significant regulatory decision point in 2026.

Unexpected Finding: GLP-1 Peptides Showing Tumor Suppression in Pancreatic Cancer Trials

A Phase I/II trial at Johns Hopkins published in Nature Medicine in January 2026 evaluated survodutide — a dual GLP-1/GIP receptor agonist developed for metabolic disease — in patients with advanced pancreatic adenocarcinoma. The results opened an entirely unexpected research direction: metabolic peptides originally designed for obesity and diabetes may have adjunct anti-cancer properties in patients with concurrent metabolic disease. The hypothesized mechanism centers on insulin signaling modulation and mitochondrial metabolic reprogramming in cancer cells. Follow-up trials are now testing mazdutide, another dual agonist, in colorectal cancer patients with metabolic syndrome. The finding is preliminary and the mechanism is not yet mapped — but it represents one of the most surprising directions in peptide research in 2026 and has significant implications for how GLP-1 compounds are studied going forward.

Google Search Data Shows Research Compound Searches Exploded After GLP-1 Mainstream Moment

A sports medicine preprint study analyzing Google search trends from 2022 through 2025 found searches for BPC-157, CJC-1295, GHK-Cu, Ipamorelin, MOTS-C, AOD-9604, and TB-500 all surged sharply starting in 2024 — preceded by Semaglutide and Tirzepatide going mainstream. The data suggests the GLP-1 wave introduced millions of people to the concept of research compounds, creating downstream interest in the broader peptide category.

Sports Medicine Boom: AOSSM Highlights Growing Provider Confusion Over Research Compounds

The American Orthopaedic Society for Sports Medicine published a feature examining the rapid expansion of research compound use among athletes and patients, noting that providers are increasingly being asked about BPC-157, TB-500, Ipamorelin, and CJC-1295 by patients who have found them online. The piece highlights that the wellness industry has expanded rapidly driven by influencer and athlete interest, placing healthcare providers in the difficult position of distinguishing evidence-based practices from commercially promoted interventions.

USC Keck School of Medicine Publishes Injectable Peptide Therapy Guide for Sports Physicians

Researchers at the University of Southern California published a primer in the American Journal of Sports Medicine evaluating injectable peptide therapy for orthopaedic injuries. The paper specifically reviews BPC-157, TB-500, CJC-1295 combined with Ipamorelin, Tesamorelin, and GHK-Cu — noting significant growth in patient demand and that the research compound market has expanded rapidly enough that mainstream medical providers now need guidance on the space.

140 Peptides Now in Active Clinical Development as Research Enters New Phase

A January 2026 review in Current Opinion in Clinical Nutrition reports that approximately 140 peptide therapeutics are currently being evaluated in clinical trials worldwide — a significant expansion from prior years. The paper covers the emerging evidence on bioactive peptides for metabolic health, cardiovascular function, and immune modulation, while noting that the gap between preclinical promise and clinical validation remains the central challenge for the field.

BPC-157 Systematic Review: 36 Studies Analyzed — Here Is What the Evidence Actually Shows

A peer-reviewed systematic review published in PMC analyzed 36 studies on BPC-157 spanning 1993 to 2024 from an orthopaedic sports medicine perspective. The review found BPC-157 promotes healing by boosting growth factors and reducing inflammation, with improved outcomes in muscle, tendon, ligament, and bone injury models in animals. The paper also clarifies BPC-157's current regulatory status — FDA Category 2 bulk substance — and notes it remains legally available as a research chemical since it is not DEA scheduled.

How to Reconstitute Research Peptides: Bacteriostatic Water, Storage, and Common Mistakes

Improper reconstitution and storage is the most common reason researchers get inconsistent results — and it's entirely preventable. This guide covers everything you need to know: why bacteriostatic water (not sterile water) is the standard choice for multi-use vials, how to calculate dilution ratios for common peptides, correct injection technique for lyophilized powders, storage conditions before and after reconstitution (most peptides: -20°C lyophilized, 4°C once reconstituted for up to 4 weeks), and the signs a vial may have degraded. Includes specific guidance for BPC-157, TB-500, CJC-1295/Ipamorelin, Semaglutide, and GHK-Cu.

PT-141 (Bremelanotide): From Tanning Peptide Research to FDA-Approved Drug — And What That Means

Bremelanotide (PT-141) holds the unusual distinction of being a peptide that went from underground research compound to FDA-approved pharmaceutical (Vyleesi, approved 2019) — the only FDA-approved treatment for acquired hypoactive sexual desire disorder in premenopausal women. Originally derived from Melanotan II research, PT-141 acts centrally on melanocortin receptors rather than peripherally like PDE5 inhibitors. Despite FDA approval of the pharmaceutical, the research-grade compound remains available from peptide vendors. This article covers the mechanism, the clinical trial history, the distinction between Vyleesi and research PT-141, and the current regulatory landscape.

BPC-157 Demonstrates Accelerated Mucosal Repair in Colitis Models

New preclinical data shows BPC-157 significantly accelerates intestinal mucosal regeneration in induced colitis models, with notable reductions in inflammatory markers and oxidative stress within 7 days of subcutaneous administration.

GHK-Cu: How a Simple Tripeptide Activates Over 4,000 Genes Involved in Tissue Repair

GHK-Cu (glycine-histidine-lysine copper complex) has attracted renewed scientific interest after genomic analysis revealed it influences the expression of over 4,000 human genes — including pathways governing wound healing, inflammation resolution, and oxidative stress. Originally isolated from human plasma in 1973 by Loren Pickart, the peptide naturally declines with age (from ~200 ng/mL at 20 to ~80 ng/mL by 60). Recent studies have expanded its known effects to include collagen stimulation, antioxidant upregulation, and potential nerve regeneration. It remains one of the few research peptides with a substantial body of published human skin studies supporting topical applications.

Retatrutide Triple Agonist Outperforms Semaglutide on Lean Mass Preservation

Post-hoc analysis of the TRIUMPH-1 trial suggests retatrutide's triple GIP/GLP-1/glucagon agonism results in superior lean muscle preservation — a key concern for researchers studying body composition outcomes.

Semax Reduces Neuroinflammatory Markers in Traumatic Brain Injury Models

Intranasal Semax administered within 6 hours of TBI significantly reduced TNF-α and IL-6 levels in cerebrospinal fluid while improving short-term memory test performance at 14-day follow-up in rodent models.

CJC-1295 + Ipamorelin: Why This Stack Became the Standard and What the Research Shows

The CJC-1295 and Ipamorelin combination has become one of the most frequently researched GH secretagogue protocols — pairing a GHRH analog (CJC-1295) with a selective ghrelin mimetic (Ipamorelin) to amplify pulsatile growth hormone release. The logic: CJC-1295 extends GH pulses by inhibiting somatostatin, while Ipamorelin adds a clean GH release signal without significant cortisol or prolactin elevation. This article reviews the published pharmacokinetics, dosing research, the case for bedtime vs morning protocols, and why the combination is frequently studied in anti-aging, sleep, and body composition contexts.

Epithalon and Telomere Length: A Review of 20 Years of Research

A comprehensive review synthesizing two decades of Epithalon research concludes the tetrapeptide demonstrates consistent telomerase activation in vitro across multiple cell lines, though human trial data remains limited.

TB-500 Accelerates Achilles Tendon Recovery in Equine Study

TB-500 injections in thoroughbred racehorses with partial Achilles tendon tears reduced recovery time by an average of 34% compared to standard rest protocols, with no adverse events recorded over 90 days.

Global Therapeutic Peptide Market Projected to Reach $78B by 2030

A new industry report values the global therapeutic peptide market at $38.2B in 2024 and projects 9.4% CAGR growth through 2030, driven by GLP-1 drug approvals, oncology peptides, and expanding research infrastructure.

Retatrutide Phase 3 Trials: Latest Updates on the Triple GLP-1/GIP/Glucagon Agonist

Retatrutide's Phase 2 data (Jastreboff et al., NEJM 2023) showed 24.2% mean weight loss at 48 weeks — surpassing tirzepatide and semaglutide in head-to-head comparisons. Eli Lilly's TRIUMPH Phase 3 program is now underway with TRIUMPH-1 targeting obesity outcomes and a dedicated cardiovascular MACE trial. Key open questions: lean mass preservation, bone effects from glucagon receptor agonism, and whether Phase 2 efficacy holds in broader populations. Regulatory submission projected no earlier than 2026.

GHK-Cu Topical Outperforms Minoxidil in Androgenic Alopecia RCT

A 24-week randomized controlled trial found a 5% GHK-Cu topical solution produced statistically superior hair follicle density increases versus 5% minoxidil in 60 male participants with early-stage androgenic alopecia.

After the Shortage List: What Actually Happened When FDA Ended Compounded Semaglutide

The FDA removed semaglutide from the drug shortage list in October 2024, ending the legal pathway for 503A/503B compounding pharmacies to produce copies of Ozempic and Wegovy. What followed was a complex legal battle: compounding pharmacy trade groups filed suit, multiple federal courts issued conflicting rulings, and the FDA enforcement posture shifted several times through early 2025. This is a comprehensive timeline of what happened, which compounders survived, how research-grade suppliers differ legally from 503A pharmacies, and what the future holds for compounded semaglutide access.

Ipamorelin Improves Deep Sleep Architecture in Middle-Aged Cohort

Polysomnography data from a 30-person pilot study found nightly Ipamorelin administration for 8 weeks significantly increased slow-wave (N3) sleep duration while reducing sleep-onset latency, consistent with known GH-secretagogue mechanisms.

Industry Group Proposes Voluntary COA Transparency Standard for Suppliers

A newly formed industry working group released a proposed framework for voluntary certificate of analysis standards among research peptide vendors, advocating for consistent third-party testing requirements and public COA accessibility.

Australia Reclassifies Several Research Peptides Under Therapeutic Goods Act

The Australian TGA updated scheduling of several peptides including Melanotan II and certain GHRP compounds, tightening import restrictions. Researchers in Australia should review current TGA scheduling before placing orders.

CagriSema Phase 3 Results: Novo's Amylin + GLP-1 Combo Shows ~20% Weight Loss

Novo Nordisk's REDEFINE-1 Phase 3 trial of cagrilintide/semaglutide (CagriSema) reported approximately 20.4% mean weight loss at 68 weeks in adults with obesity — placing it between tirzepatide and retatrutide in the GLP-1 landscape. CagriSema combines the GLP-1 receptor agonist semaglutide with cagrilintide, an amylin analog targeting the calcitonin receptor. The combination addresses complementary satiety pathways, and Novo filed for regulatory review in early 2025. Notably, CagriSema's profile may offer advantages in gastric emptying tolerability for some patients who experience nausea with pure GLP-1 monotherapies.

MOTS-C and Longevity: What the Research Actually Shows About This Mitochondrial Peptide

MOTS-c is encoded in mitochondrial DNA — not the nuclear genome — a fact that sets it apart from nearly every other compound in aging research. The Lee et al. 2015 Cell Metabolism paper established its role as a mitochondria-to-nucleus retrograde signal that regulates glucose and lipid metabolism. Population data shows elevated MOTS-c in centenarians and metabolically healthy elderly adults. Exercise increases circulating MOTS-c, and exogenous MOTS-c mimics aspects of aerobic exercise in rodent models. The honest summary: compelling animal data, thin human clinical evidence, and significant unknowns around dosing, half-life, and long-term safety.